Hillel v. IQVIA, Inc.

CourtCourt of Appeals for the Second Circuit
DecidedMarch 29, 2022
Docket21-666-cv
StatusUnpublished

This text of Hillel v. IQVIA, Inc. (Hillel v. IQVIA, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hillel v. IQVIA, Inc., (2d Cir. 2022).

Opinion

21-666-cv Hillel v. IQVIA, Inc.

UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

SUMMARY ORDER Rulings by summary order do not have precedential effect. Citation to a summary order filed on or after January 1, 2007, is permitted and is governed by Federal Rule of Appellate Procedure 32.1 and this Court’s Local Rule 32.1.1. When citing a summary order in a document filed with this Court, a party must cite either the Federal Appendix or an electronic database (with the notation “summary order”). A party citing a summary order must serve a copy of it on any party not represented by counsel.

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 29th day of March, two thousand twenty-two.

PRESENT: JOSÉ A. CABRANES, REENA RAGGI, SUSAN L. CARNEY, Circuit Judges.

IRIS HILLEL,

Plaintiff-Appellant, 21-666-cv

v.

IQVIA, INC.,

Defendant-Appellee,

OBVIO HEALTH USA, INC., OBVIO HEALTH PTE. LTD., SPRIM AMERICAS, INC., MICHAEL SHLEIFER, in his individual and professional capacity, PRASANNA PITALE, in his individual and professional capacity, ALISTAIR GRENFELL, in his individual and professional capacity, DIKLA SHPANGENTAL, in her individual and professional capacity, ANAND THARMARATNAM, in his individual and professional capacity, IVAN JARRY, in his individual and professional capacity,

1 Defendants. *

FOR PLAINTIFF-APPELLANT: LINDSAY M. GOLDBRUM (Michael J. Willemin, on the brief), Wigdor LLP, New York, NY.

FOR DEFENDANT-APPELLEE: KENNETH W. TABER (Maria T. Galeno, Stephanie M. Coughlan, on the brief), Pillsbury Winthrop Shaw Pittman LLP, New York, NY.

Appeal from an order and judgment of the United States District Court for the Southern District of New York (Loretta A. Preska, Judge).

UPON DUE CONSIDERATION WHEREOF, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that the January 21, 2021 order and March 9, 2021 judgment of the District Court be and hereby are VACATED insofar as they dismissed Plaintiff Iris Hillel’s defamation and tortious interference claims based on Anand Tharmaratnam’s alleged statement, AFFIRMED in all other respects, and the cause is REMANDED to the District Court for further proceedings consistent with this order.

Plaintiff Iris Hillel alleges that her former employer ObvioHealth (“Obvio”) and its owner and employees fired her in violation of federal, state, and local antidiscrimination statutes, and that Defendant IQVIA, Inc. (“IQVIA”) and its employees defamed her and tortiously interfered with her prospective economic relations in violation of New York law. Hillel alleges four defamatory statements by IQVIA’s employees. First, Anand Tharmaratnam allegedly told two of Hillel’s colleagues that Hillel had been fired from her job with IQVIA’s predecessor. Second, Alistair Grenfell allegedly told one of his IQVIA colleagues, Prasanna Pitale, that Grenfell did not want Hillel to work with IQVIA in Europe. Third, Dikla Shpangental allegedly told the same IQVIA colleague that Shpangental would not attend meetings with Obvio if Hillel was present. Fourth, Pitale allegedly informed Hillel’s Obvio colleague of the remarks by Grenfell and Shpangental. 1 Hillel alleges that these statements caused her to be fired and lose her $300,000 annual salary and bonus.

* The Clerk of Court is directed to amend the caption as set forth above. 1 Tharmaratnam was IQVIA’s President for Asia Pacific. Grenfell is IQVIA’s President for Europe, the Middle East, Africa, and South Asia. Shpangental is IQVIA’s Vice President for Israel. Pitale is IQVIA’s Senior Vice President of Global Consumer Health and a member of Obvio’s Board of Directors.

2 The District Court granted IQVIA’s motion to dismiss pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. 2 It held that IQVIA’s employees’ statements were protected by New York’s common interest privilege. It held alternatively that the statements of Grenfell, Shpangental, and Pitale were nonactionable opinion. Finally, it dismissed Hillel’s tortious interference claim because she alleged neither malice nor an independent tort. Finding no just reason for delay, the District Court entered final judgment for IQVIA and its employees pursuant to Rule 54(b) of the Federal Rules of Civil Procedure, and Hillel appealed the judgment in favor of IQVIA. We assume the parties’ familiarity with the underlying facts, the procedural history of the case, and the issues on appeal.

We review the District Court’s holdings on a motion to dismiss de novo, “accepting all factual allegations in the complaint as true and drawing all reasonable inferences in favor of the plaintiff.” Caro v. Weintraub, 618 F.3d 94, 97 (2d Cir. 2010).

I.

We first consider the primary basis on which the District Court dismissed Hillel’s defamation claims: common interest privilege. This was error.

The common interest privilege “extends to a communication made by one person to another upon a subject in which both have an interest.” Chandok v. Klessig, 632 F.3d 803, 815 (2d Cir. 2011) (citation omitted). Hillel does not allege that the challenged statements concerned a subject of common interest to IQVIA and Obvio. True, she alleges that these businesses shared a common interest in negotiating and executing a large deal involving significant collaboration between the two companies. But Hillel does not allege that this deal was “the subject matter of [the allegedly defamatory] communications,” Loewinthan v. Le Vine, 299 N.Y. 372, 375 (1949), nor that the challenged statement “was reasonably calculated to serve this [common] interest,” Buckley v. Litman, 57 N.Y.2d 516, 521 (1982).

Instead, Hillel alleges that the statements sought to shake Obvio’s confidence in her, undermining Obvio’s ability to compete with IQVIA during a six-month period permitted under the companies’ deal agreement. Plainly, Obvio shared no common interest with IQVIA in so undermining its ability to compete. See, e.g., Rupert v. Sellers, 411 N.Y.S.2d 75, 82–83 (4th Dep’t 1978) (“There . . . is no qualified privilege to make a defamatory attack merely to protect one’s business interest”), aff’d, 50 N.Y.2d 881 (1980). Because the statements allegedly attributable to IQVIA, viewed in this anti-competitive context, were not related to “the flow of information between persons sharing a common interest,” Liberman v. Gelstein, 80 N.Y.2d 429, 437 (1992), it was error at

2 The District Court granted IQVIA’s employees’ motion to dismiss pursuant to Rule 12(b)(2) for lack of personal jurisdiction. Hillel does not contest this ruling on appeal.

3 this stage to dismiss Hillel’s claims based on the common interest privilege. We thus need not consider Hillel’s remaining arguments regarding the privilege.

II.

We next consider the District Court’s alternative basis for dismissing Hillel’s defamation claims: that certain statements are non-actionable opinion. This holding was sound.

The District Court correctly held that Grenfell’s and Shpangental’s—and, therefore, Pitale’s—statements were not actionable. Their statements—that they did not want Hillel to work with IQVIA and would not attend meetings with Hillel—express their personal views and opinions and do not imply any facts beyond their plain meanings, which Hillel does not allege were literally false.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Caro v. Weintraub
618 F.3d 94 (Second Circuit, 2010)
Chandok v. Klessig
632 F.3d 803 (Second Circuit, 2011)
Kirch v. Liberty Media Corp.
449 F.3d 388 (Second Circuit, 2006)
Carvel Corp. v. Noonan
818 N.E.2d 1100 (New York Court of Appeals, 2004)
Loewinthan v. Le Vine
87 N.E.2d 303 (New York Court of Appeals, 1949)
Rupert v. Sellers
408 N.E.2d 671 (New York Court of Appeals, 1980)
Buckley v. Litman
443 N.E.2d 469 (New York Court of Appeals, 1982)
Liberman v. Gelstein
605 N.E.2d 344 (New York Court of Appeals, 1992)
Colantonio v. Mercy Medical Center
73 A.D.3d 966 (Appellate Division of the Supreme Court of New York, 2010)
Rupert v. Sellers
65 A.D.2d 473 (Appellate Division of the Supreme Court of New York, 1978)
Stega v. New York Downtown Hosp.
31 N.Y.3d 661 (New York Court of Appeals, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Hillel v. IQVIA, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/hillel-v-iqvia-inc-ca2-2022.